Status:
COMPLETED
Evaluation of the INDICAID™ COVID-19 Rapid Antigen Test
Lead Sponsor:
University of California, Los Angeles
Conditions:
Covid19
Eligibility:
All Genders
5+ years
Brief Summary
The INDICAID™ Rapid Antigen Test was used in real-world outbreak testing. The antigen test was used together with PCR testing. This study was designed to evaluate whether the addition of a rapid antig...
Detailed Description
Description of the INDICAID™ COVID-19 Rapid Antigen Test The INDICAID™ Rapid Test by PHASE Scientific is a LFA designed for the qualitative detection of SARS-CoV-2 nucleocapsid protein in nasal swab s...
Eligibility Criteria
Inclusion
- at least 5 years of age and report onset
- at least two of the following COVID-19 symptoms within 5 days or less: fever or chills, fatigue, sore throat, congestion or runny nose, cough, headache, diarrhea, shortness of breath or difficulty breathing, muscle or body aches, new loss of taste or smell, nausea, or vomiting.
Exclusion
- That do not fit inclusion criteria or vulnerable populations
Key Trial Info
Start Date :
November 20 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 9 2021
Estimated Enrollment :
297 Patients enrolled
Trial Details
Trial ID
NCT04904510
Start Date
November 20 2020
End Date
March 9 2021
Last Update
February 15 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CityHealth Urgent Care Oakland
Oakland, California, United States, 94612